COVID-19 Vaccine Booster Dose Acceptance: Systematic Review and Meta-Analysis
Overview
Authors
Affiliations
The World Health Organization (WHO) recommended coronavirus disease 2019 (COVID-19) booster dose vaccination after completing the primary vaccination series for individuals ≥18 years and most-at-risk populations. This study aimed to estimate the pooled proportion of COVID-19 vaccine booster dose uptake and intention to get the booster dose among general populations and healthcare workers (HCWs). We searched PsycINFO, Scopus, EBSCO, MEDLINE Central/PubMed, ProQuest, SciELO, SAGE, Web of Science, Google Scholar, and ScienceDirect according to PRISMA guidelines. From a total of 1079 screened records, 50 studies were extracted. Meta-analysis was conducted using 48 high-quality studies according to the Newcastle-Ottawa Scale quality assessment tool. Using the 48 included studies, the pooled proportion of COVID-19 vaccine booster dose acceptance among 198,831 subjects was 81% (95% confidence interval (CI): 75-85%, = 100%). The actual uptake of the booster dose in eight studies involving 12,995 subjects was 31% (95% CI: 19-46%, = 100%), while the intention to have the booster dose of the vaccine was 79% (95% CI: 72-85%, = 100%). The acceptance of the booster dose of COVID-19 vaccines among HCWs was 66% (95% CI: 58-74%), = 99%). Meta-regression revealed that previous COVID-19 infection was associated with a lower intention to have the booster dose. Conversely, previous COVID-19 infection was associated with a significantly higher level of booster dose actual uptake. The pooled booster dose acceptance in the WHO region of the Americas, which did not include any actual vaccination, was 77% (95% CI: 66-85%, = 100%). The pooled acceptance of the booster dose in the Western Pacific was 89% (95% CI: 84-92%, = 100), followed by the European region: 86% (95% CI: 81-90%, = 99%), the Eastern Mediterranean region: 59% (95% CI: 46-71%, = 99%), and the Southeast Asian region: 52% (95% CI: 43-61%, = 95). Having chronic disease and trust in the vaccine effectiveness were the significant predictors of booster dose COVID-19 vaccine acceptance. The global acceptance rate of COVID-19 booster vaccine is high, but the rates vary by region. To achieve herd immunity for the disease, a high level of vaccination acceptance is required. Intensive vaccination campaigns and programs are still needed around the world to raise public awareness regarding the importance of accepting COVID-19 vaccines needed for proper control of the pandemic.
Kitro A, Sirikul W, Polpitakchai C, Panumasvivat J, Yamsiri R, Tasena P Vaccines (Basel). 2025; 12(12.
PMID: 39772043 PMC: 11680416. DOI: 10.3390/vaccines12121381.
White T, Wyka K, Rabin K, El-Mohandes A Vaccine X. 2024; 21:100576.
PMID: 39555242 PMC: 11566880. DOI: 10.1016/j.jvacx.2024.100576.
Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023.
Jeong Y, Park S, Lee S, Jang W, Park J, Lee K Sci Rep. 2024; 14(1):24561.
PMID: 39427003 PMC: 11490553. DOI: 10.1038/s41598-024-74729-2.
Evidence brief on facilitators, barriers and hesitancy of COVID-19 booster doses in Canada.
Young K, Corrin T, Pussegoda K, Baumeister A, Waddell L Can Commun Dis Rep. 2024; 50(10):338-344.
PMID: 39380803 PMC: 11460581. DOI: 10.14745/ccdr.v50i10a02.
El Tantawi M, Elwan A, Hassan R, Mohamed N, Elsheikh E, Hassan H Sci Rep. 2024; 14(1):22795.
PMID: 39353979 PMC: 11445433. DOI: 10.1038/s41598-024-72093-9.